Latest news
Dyne Therapeutics, Inc. Revenue Breakdown – NASDAQ:DYN - TradingViewTradingView · Thu, 06 Aug 2026 23:21:02 GMTWeekly Recap: BLA accepted for Z‑Rostudirsen and RBC raises PT to $35 - TradingViewTradingView · Mon, 03 Aug 2026 11:33:16 GMTDyne Therapeutics, Inc. Stock 12‑Month Price Target Raised to $39.53, Implies 58% Upside - TradingViewTradingView · Thu, 30 Jul 2026 07:00:00 GMTDyne Therapeutics reports Q2 net loss $178.6M, cash $898.5M; BLA for z-rostudirsen accepted with PDUFA Jan 21, 2027 - TradingViewTradingView · Wed, 29 Jul 2026 20:43:04 GMTDyne Therapeutics reports larger-than-expected Q2 net loss per share - TradingViewTradingView · Wed, 29 Jul 2026 07:00:00 GMTDyne Therapeutics, Inc. Q2 2026: Net loss $178.6M, EPS $(1.08) — 10-Q Summary - TradingViewTradingView · Wed, 29 Jul 2026 07:00:00 GMTDYN: FDA Priority Review for z-rostudirsen and strong cash position support growth into 2028 - TradingViewTradingView · Wed, 29 Jul 2026 07:00:00 GMTWeekly Recap: Upsized offering raises ~$375M and BLA for DYNE-251 - TradingViewTradingView · Mon, 27 Jul 2026 07:00:00 GMT